Effect of cinepazide combined with mecobalamine on nerve conduction velocity, vibration perception threshold and serum indexes in patients with diabetic peripheral neuropathy

Objective:To analyze the effect of cinepazide combined with mecobalamine on nerve conduction velocity, vibration perception threshold and serum indexes in patients with diabetic peripheral neuropathy. Methods:90 patients with diabetic peripheral neuropathy treated in our hospital between March 2013 and March 2016 were selected and divided into observation group and control group (n=45) according to random number table, control group received mecobalamine treatment alone and observation group accepted the cinepazide combined with mecobalamine therapy. Differences in nerve conduction velocity, vibration perception threshold as well as serum oxidative stress indexes and nerve injury marker molecules were compared between two groups of patients 2 weeks after treatment. Results:2 weeks after treatment, median nerve, ulnar nerve and peroneal nerve sensory nerve conduction velocity (SNCV) and motor nerve conduction velocity (MNCV) levels of observation group were higher than those of control group (P<0.05) while both lower extremities vibration perception threshold (VPT) levels were lower than those of control group (P<0.05). Serum homocysteine (HCY), advanced glycosylation end products (AGEs), malondialdehyde (MDA), neuron-specific enolase (NSE), high mobility group B1 (HMGB1) and S100βcontent of observation group were lower than those of control group (P<0.05) while reduced glutathione (GSH), superoxide dismutase (SOD), myelin basic protein (MBP) and brain-derived neurotrophic factor (BDNF) content were higher than those of control group (P<0.05). Conclusions:Cinepazide combined with mecobalamine can reduce the nerve injury degree, improve nerve conduction and vibration perception and alleviate the oxidative stress degree in patients with diabetic peripheral neuropathy.

Effects of pestle needle on nerve conduction velocity and inflammatory injury in patients with diabetic peripheral neuropathy

Background:Diabetic peripheral neuropathy(DPN)is one of the most common complications of diabetes mellitus.Impaired neurological function is one of the main characteristics of DPN and is strongly associated with the inflammatory response.Our previous studies have confirmed that pestle needle can improve the nerve function of patients with DPN.But the mechanism of pestle needle treatment of DPN is still unclear.Methods:A total of 70 DPN patients who met the inclusion criteria were randomly divided into two groups.Control group(CG)(n=35)received DPN conventional treatment and the pestle needle group(PNG)(n=35)received pestle needle therapy at Zhiyang(DU09)eight array,Mingmen(DU04)eight array and Heche Road(from Mingmen(DU04)to Changqiang(DU01)),Zusanli(ST36),Sanyinjiao(SP06),Taixi(KI03)and Yongquan(KI01).Patients in the PNG group were required to take this treatment for 4 weeks,5 times a week.Examination indexes were collected before and after treatment,respectively.Nerve function was examined using the Toronto clinical scoring system and nerve conduction velocity detection.Serum inflammatory factors were measured by enzyme linked immunosorbent assay.Results:The Toronto clinical scoring system was significantly reduced in the PNG compared with the CG after treatment.The sensory nerve conduction velocity and motor nerve conduction velocity of the right peroneal and median nerves were significantly faster in the PNG than those in the CG(P<0.05).After treatment,serum interleukin-1 beta,interleukin-6 and tumor necrosis factor-alpha levels decreased in both groups,and the improvement of PNG was better than CG(P<0.05).Conclusion:The pestle needle can significantly improve the symptoms and nerve conduction velocity of DPN,and its mechanism may be related to the reduction of inflammatory factors.

Abnormality of peripheral nerve conduction velocity associated with illness course, symptoms and fasting blood glucose in patients with type 2 diabetes mellitus

BACKGROUND: It has shown that abnormality of peripheral nerve conduction velocity during onset of diabetes mellitus is not related to age and sex, but to symptoms, illness course and level of fasting blood glucose. OBJECTIVE: To measure correlation of abnormality of peripheral nerve conduction velocity with various illness courses, symptoms and levels of fasting blood glucose of patients with type 2 diabetes mellitus. DESIGN: Case analysis. SETTING: Department of Neurology, Central People's Hospital of Huizhou. PARTICIPANTS: A total of 128 patients who were diagnosed as type 2 diabetes mellitus were selected from Central People's Hospital of Huizhou from September 2001 to October 2005. There were 75 males and 53 females aged 32-83 years and the illness course ranged from 1 month to 20 years. METHODS: All 128 patients with type 2 diabetes mellitus received neuro-electrophysiological study and their clinical data were retrospectively analyzed to measure peripheral nerve conduction velocity and fasting blood glucose so as to investigate the correlation of peripheral nerve conduction velocity with clinical symptoms, illness course and levels of fasting blood glucose. MAIN OUTCOME MEASURES: Correlation of peripheral nerve conduction velocity with clinical symptoms, illness course and levels of fasting blood glucose. RESULTS: All 128 patients with type 2 diabetes mellitus were involved in the final analysis. ① Among 128 patients, 114 patients had abnormality of peripheral nerve conduction velocity; 110 patients had clinical symptoms, including 102 patients having abnormality of peripheral nerve conduction velocity; 18 patients did not have clinical symptoms, including 12 patients having abnormality of peripheral nerve conduction velocity. There were significant differences between them (χ 2=8.275, P =0.04). ② Among 128 patients, illness course of 75 patients was equal to or less than 5 years, including 27 patients having abnormality of peripheral nerve conduction velocity; illness course of 53 patients was more than 5 years, including 35 patients having abnormality of peripheral nerve conduction velocity. There were significant differences between them (χ 2=11.469, P =0.003). ③ Among 128 patients, levels of fasting blood glucose of 75 patients was equal to or lower than 11 mmol/L, including 41 patients having abnormality of peripheral nerve conduction velocity; levels of fasting blood glucose of 53 patients was higher than 11 mmol/L, including 38 patients having abnormality of peripheral nerve conduction velocity. There were significant differences between them (χ 2=4.023, P =0.134). CONCLUSION: ① Abnormality of peripheral nerve conduction velocity of patients with type 2 diabetes mellitus is related to illness courses and clinical symptoms. The longer the illness course is, the severer the abnormality of peripheral nerve conduction velocity is. Abnormality of peripheral nerve conduction velocity always occurs on patients who have clinical symptoms. ② Abnormality of peripheral nerve conduction velocity is not related to levels of fasting blood glucose.

CLINICAL AND ELECTROPHYSIOLOGICAL OBSERVATIONS ON DIABETIC PERIPHERAL NEUROPATHYTREATED BY WARM NEEDLING AND MOXIBUSTION

Objective To observe clinical therapeutic effects of warm needling and moxibustion on diabetic peripheral neuropathy （DPN） and their influence on nerve conduction velocity. Methods Fifty two cases were randomly divided into a treatment group （n =26） and a control group （n =26）. In addition to basic treatment for lowering blood sugar in both groups, Pǐshū （BL 20）, Shènshū （BL 23）, Huántiào （GB 30）, Zùsānlǐ （ST 36）, Yánglíngquán （GB 34）, Sānyīnjiāo （SP 6）, Tàixī （KI 3）, Qǔchí （LI 11）, Wàiguān （TE 5） and Hégǔ （LI 4） were selected for warm needling and moxibustion in the treatment group. Methycobal was intramuscularly injected in the control group. Clinical symptoms and conduction velocities of the tibial nerve and common peroneal nerve were compared before and after treatment. Results Warm needling and moxibustion could alleviate such clinical symptoms as numbness of limbs, pain and hypoesthesia, and obviously improve the conduction velocities of both tibial and common peroneal nerves. Conclusion Warm needling and moxibustion exhibit good therapeutic effects on diabetic peripheral neuropathy.

Huangqi Guizhi Wuwu Decoction for treating diabetic peripheral neuropathy：a meta-analysis of 16 randomized controlled trials

OBJECTIVE：This meta-analysis was performed to systematically assess the efficacy and safety of the Chinese herbal medicine Huangqi Guizhi Wuwu Decoction（HGWWD） for treating diabetic peripheral neuropathy.DATA SOURCES：Six electronic databases,including the Cochrane Library,MEDLINE database,Chinese Biomedical Database,Chinese National Knowledge Infrastructure Database,Chinese Science and Technique Journals Database,and the Wanfang Database,were search ed on the internet for randomized controlled trials published up until 1 December 2015.The search terms included ＂Chinese herbal medicine＂,＂diabetic peripheral neuropathy＂ and ＂randomized controlled trials＂ in Chinese and in English.DATA SELECTION：We included randomized controlled trials using HGWWD/modified HGWWD for the treatment group,without restriction for the control group.We assessed literature quality in accordance with the Cochrane Review Handbook.A random or a fixed effects model was used to analyze outcomes using Rev Man 5.2 software.OUTCOME MEASURES：The primary outcomes were changes in symptoms and nerve conduction velocities.The secondary outcomeswere fasting blood glucose and hemorheological indexes.RESULTS：Sixteen randomized controlled trials,with a total of 1,173 patients,were included.Meta-analysis revealed that the efficacy of HGWWD for diabetic peripheral neuropathy was significantly superior compared with the control treatment（i.e.,control group）（risk ratio = 0.36,95% confidence interval（CI）：0.29–0.46,Z =8.33,P 〈 0.00001） Compared with the control group,there was an increase in median motor nerve conduction velocity（mean difference（MD） = 3.46,95%CI：1.88–5.04,Z = 4.30,P 〈 0.01） and median sensory nerve conduction velocity（MD = 3.30,95%CI：2.04–4.56,Z = 5.14,P 〈 0.01）.There was also an increase in peroneal motor nerve conduction velocity（MD = 3.22,95%CI：2.45–3.98,Z = 8.21,P 〈 0.01） and peroneal sensory nerve conduction velocity（MD = 3.05,95%CI：2.01–4.09,Z = 5.75,P 〈 0.01） in the treatment groups.No significant difference in fasting blood glucose was found between the treatment groups and the control groups（MD =-0.12,95%CI：-0.42–0.19,Z = 0.76,P = 0.45）.Plasma viscosity was significantly decreased after treatment（MD =-0.11,95%CI：-0.21 to-0.02,Z = 2.30,P = 0.02）.No significant difference in fibrinogen was detectable（MD =-0.53,95%CI：-1.28–0.22,Z = 1.38,P = 0.17）.Four trials reported that treatment groups experienced no adverse reactions.Adverse events were not mentioned in the other 12 trials.No trial reported the incidence of complications,quality of life outcomes,or health economics.CONCLUSION：HGWWD treatment improves diabetic neurologic symptoms and ameliorates nerve conduction velocities.Our study suggests that HGWWD may have significant therapeutic efficacy for the treatment of diabetic peripheral neuropathy.However,the methodological quality of the randomized controlled trials was generally low.Larger and better-designed randomized controlled trials are required to more reliably assess the clinical effectiveness of HGWWD.

Efficacy of epalrestat plus α-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials

OBJECTIVE： To evaluate the efficacy of α-lipoic acid（ALA） plus epalrestat combination therapy in the treatment of diabetic peripheral neuropathy（DPN）. DATA SOURCES： The electronic databases of Pub Med, Medline, Embase, the Cochrane Library, the Chinese National Knowledge Infrastructure, the Wanfang Database and the Chinese Biomedical Database were used to retrieve relevant studies without language restrictions. The search was conducted from the inception of each database to 7 October 2016. The key terms were（diabetic peripheral neuropathy or diabetic neuropathy or DPN） AND（α-lipoic acid or lipoic acid or thioctic acid） AND epalrestat. DATA SELECTION： All of the eligible studies met the following inclusion criteria：（1） Randomized controlled trials that compared efficacy and safety of epalrestat plus ALA combination therapy versus epalrestat or ALA monotherapy in patients with DPN.（2） The minimum duration of treatment was 2 weeks.（3） The DPN patients were diagnosed using the World Health Organization standardized type 2 diabetes mellitus and DPN criteria.（4） Studies contained at least one measure that could reflect the efficacy of the drug and nerve conduction velocities. Studies in which the control group used epalrestat or ALA combined with other drugs were excluded. Statistical analyses were performed using STATA software for meta-analysis. OUTCOME MEASURES： The primary outcomes were the therapeutic efficacy, median motor nerve conduction velocity（MNCV）, median sensory nerve conduction velocity（SNCV）, peroneal MNCV and peroneal SNCV.RESULTS： Twenty studies with 1894 DPN patients were included, including 864 patients in the ALA plus epalrestat group, 473 in the ALA group and 557 in the epalrestat group. The efficacy of ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies（RR = 1.29, 95% CI： 1.21–1.38; RR = 1.43, 95% CI： 1.34–1.54, respectively）. ALA plus epalrestat combination therapy also significantly improved median MNCV（WMD = 5.41, 95% CI： 2.07–8.75）, median SNCV（WMD = 5.87, 95% CI： 1.52–10.22）, peroneal MNCV（WMD = 5.59, 95% CI： 2.70–8.47） and peroneal SNCV（WMD = 4.57, 95% CI： 2.46–6.68）.CONCLUSION： ALA plus epalrestat combination therapy was superior to ALA and epalrestat monotherapies for clinical efficacy and nerve conduction velocities in patients with DPN.

Intraoperative single administration of neutrophil peptide 1 accelerates the early functional recovery of peripheral nerves after crush injury

Neutrophil peptide 1 belongs to a family of peptides involved in innate immunity. Continuous intramuscular injection of neutrophil peptide 1 can promote the regeneration of peripheral nerves, but clinical application in this manner is not convenient. To this end, the effects of a single intraoperative administration of neutrophil peptide 1 on peripheral nerve regeneration were experimentally observed. A rat model of sciatic nerve crush injury was established using the clamp method. After model establishment, a normal saline group and a neutrophil peptide 1 group were injected with a single dose of normal saline or 10 μg/mL neutrophil peptide 1, respectively. A sham group, without sciatic nerve crush was also prepared as a control. Sciatic nerve function tests, neuroelectrophysiological tests, and hematoxylin-eosin staining showed that the nerve conduction velocity, sciatic functional index, and tibialis anterior muscle fiber cross-sectional area were better in the neutrophil peptide 1 group than in the normal saline group at 4 weeks after surgery. At 4 and 8 weeks after surgery, there were no differences in the wet weight of the tibialis anterior muscle between the neutrophil peptide 1 and saline groups. Histological staining of the sciatic nerve showed no significant differences in the number of myelinated nerve fibers or the axon cross-sectional area between the neutrophil peptide 1 and normal saline groups. The above data confirmed that a single dose of neutrophil peptide 1 during surgery can promote the recovery of neurological function 4 weeks after sciatic nerve injury. All the experiments were approved by the Medical Ethics Committee of Peking University People's Hospital, China(approval No. 2015-50) on December 9, 2015.

Efficacy evaluation of high-frequency ultrasound in the treatment of diabetic peripheral neuropathy with α-lipoic acid combined with traditional Chinese medicine package treatment

Objective:To use high-frequency ultrasound to evaluate the efficacy ofα-lipoic acid combined with traditional Chinese medicine in the treatment of diabetic peripheral neuropathy(DPN),so as to provide a basis for clinical medication and evaluation of therapeutic effect.Methods:From December 2018 to December 2019,110 patients with DPN who met the inclusion and exclusion criteria were divided into observation group and control group according to different treatment plans.The control group was treated withα-lipoic acid,and the observation group was treated withα-lipoic acid combined with traditional Chinese medicine encapsulation treatment,and used high-frequency ultrasound,nerve conduction velocity and serological examination to comprehensively evaluate the effectiveness of the two treatment methods.Results:The mean amplitude of glycemic excursions(MAGE)value of the observation group and the control group after treatment was significantly lower than before treatment(P<0.05);After treatment,the SCV of the ulnar nerve,median nerve,and common peroneal nerve in the two groups was significantly faster than before treatment(P<0.05).Similar to SCV,the MCV of the three nerves measured after treatment in the two groups was significantly faster than before treatment(P<0.05).Compared between the groups after treatment,the three kinds of nerve SCV and MCV in the observation group were significantly faster than those in the control group(P<0.05).The cross-sectional area(CSA)value of the ulnar nerve,median nerve and common peroneal nerve in the observation group after treatment was significantly lower than before treatment(P<0.05).Compared with the control group after treatment,the three nerves CSA in the observation group was significantly lower than that in the control group(P<0.05).Abnormal ultrasound performance:The proportion of abnormal ultrasound performances of the ulnar nerve,median nerve,and common peroneal nerve in the observation group after treatment was significantly lower than before treatment(P<0.05).The composition ratio of internal echo reduction and ambiguity in the observation group after three nerve treatments was significantly lower than that in the control group after treatment(P<0.05).In the correlation analysis,the three kinds of nerve CSA before and after treatment were negatively correlated with SCV and amplitude(P<0.05),and positively correlated with latency(P<0.05).Conclusion:The combination ofα-lipoic acid and Chinese medicine encapsulation technology has a good effect on the treatment and repair of DPN nerve damage,and can be routinely applied in clinical treatment.High-frequency ultrasound can intuitively observe changes in peripheral nerves and can be used to evaluate the prognosis of DPN.

Correlation between serum homocysteine content and the changes in patients with type 2 diabetic peripheral neuropathy

Objective:To study the correlation between serum homocysteine (Hcy) content and the changes in patients with type 2 diabetic peripheral neuropathy (DPN).Methods: The patients who were diagnosed with T2DM between March 2015 and April 2018 in our hospital were chosen and divided into the DPN group combined with DPN and the T2DM group not combined with DPN;healthy volunteers were chosen as the control group. The serum contents of Hcy, folic acid (FA), vitamin B12 (VitB12), inflammation indexes and oxidation indexes as well as sensory nerve conduction velocity (SCV) in extremities were measured.Results:Serum Hcy, soluble vascular cell adhesion molecule-1 (sVCAM-1), interleukin-1β (IL-1β) and high mobility group B1 (HMGB1) contents of DPN group were significantly higher than those of T2DM group and control group while serum FA, VitB12, superoxide dismutase (SOD) and glutathione peroxidase (GSH) contents as well as median nerve, ulnar nerve, radial nerve, common peroneal nerve and tibial nerve SCV levels were significantly lower than those of T2DM group and control group;serum sVCAM-1, IL-1β and HMGB1 contents significantly increased while serum SOD and GSH contents as well as median nerve, ulnar nerve, radial nerve, common peroneal nerve and tibial nerve SCV levels significantly decreased in DPN group of patients with hyperhomocysteinemia.Conclusion: Serum Hcy content significantly increases in patients with DPN, and it can aggravate the nerve conduction function injury and activate the inflammatory and oxidative reaction.

依帕司他联合丁苯酞软胶囊对痛性糖尿病周围神经病变患者的影响

目的:分析依帕司他联合丁苯酞软胶囊对痛性糖尿病周围神经病变(PDPN)患者的影响。方法:选取2021年2月—2022年2月通城县人民医院收治的80例PDPN患者作为研究对象,根据掷硬币法将患者分为对照组和研究组,各40例。对照组给予依帕司他,研究组在对照组基础上给予丁苯酞软胶囊,比较两组临床疗效、不良反应、疼痛程度[视觉模拟评分法(VAS)]、正中神经、腓总神经、尺神经的感觉神经传导速度(SNCV)、运动神经传导速度(MNCV)及氧化应激指标[超氧化物歧化酶(SOD),丙二醛(MDA)]水平。结果:研究组临床总有效率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);治疗1个月后,两组VAS评分低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗1个月后,两组正中神经、腓总神经、尺神经的SNCV和MNCV较治疗前提高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗1个月后,两组SOD和MDA水平较治疗前改善,且研究组SOD水平高于对照组,MDA水平低于对照组,差异有统计学意义(P<0.05)。结论:依帕司他与丁苯酞软胶囊联合治疗PNDN,临床疗效好,不良反应发生率较低,能显著降低疼痛程度,提高正中神经、腓总神经、尺神经SNCV和MNCV,改善SOD和MDA水平。

甲钴胺联合依帕司他治疗糖尿病周围神经病变的效果及对患者周围神经传导速度的影响

目的探讨甲钴胺联合依帕司他治疗糖尿病周围神经病变(DPN)的效果。方法将78例DPN患者随机分为两组。对照组应用甲钴胺治疗,观察组则在对照组基础上采用依帕司他治疗。比较两组患者的疗效、神经传导速度与不良反应发生率。结果观察组总有效率为97.44%,高于对照组的82.05%(P<0.05)。治疗后,观察组运动神经与感觉神经传导速度均高于对照组(P<0.05)。两组的不良反应发生率比较无统计学差异(P>0.05)。结论甲钴胺联合依帕司他治疗DPN具有较好的效果,可提高神经传导速度,加速患者病症改善,临床价值显著。

硫辛酸胶囊联合甲钴胺片治疗糖尿病周围神经病变的临床疗效

目的 分析硫辛酸胶囊的基础上辅助甲钴胺片治疗糖尿病周围神经病变(DPN)患者的临床效果。方法 本文的研究对象为80例糖尿病周围神经病变患者,根据随机数字法主要分为观察组与对照组。对照组40例患者均以甲钴胺片进行治疗,观察组40例患者均以硫辛酸胶囊联合甲钴胺片治疗。对比两组的临床疗效、运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)、多伦多临床评分系统(TCSS)评分。结果 对比于对照组,观察组患者的总有效率明显较高(P<0.05)。治疗后,与对照组对比,观察组患者MNCV与SNCV升高(P<0.05)。治疗后与对照组对比,观察组患者的TCSS评分较低(P<0.05)。结论 以硫辛酸胶囊辅助甲钴胺片治疗DPN患者可改善运动神经传导速度、感觉神经传导速度,延缓疾病进展,提升治疗效果,值得临床借鉴、推广。

糖尿病周围神经病变经当归四逆汤治疗后的神经传导速度与疗效观察

目的探讨糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)经当归四逆汤治疗后的神经传导速度与疗效。方法采用随机数字表法将104例于2021年12月—2022年12月在河南省中医院接受治疗的DPN患者分为A组和B组,各52例。B组患者采用常规治疗,A组在B组基础上给予当归四逆汤治疗。以4周为1个周期,两组均维持治疗1个周期。比较两组治疗4周后的临床疗效,治疗前、治疗4周后的中医证候评分、血清学指标、血糖指标、神经传导情况及治疗期间的不良反应发生情况。结果与B组比较,A组治疗4周后的临床总有效率较高,[98.08%(51/52)vs 84.62%(44/52)];相较于治疗前,两组治疗4周后的肌肉萎缩、感觉减退、肢体麻木、四肢疼痛、四肢发凉各项评分、血清餐后2 h血糖(2 h postprandial blood glucose,2 h PBG)、糖化血红蛋白(glycated hemoglobin,HbA1c)、丙二醛(malondialdehyde,MDA)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-23(interleukin-23,IL-23)水平、胰岛素抵抗指数(insulin resistance index,HOMA-IR)值均降低,且相较于B组,A组更低,两组治疗4周后的正中神经感觉神经传导速度(sensory nerve conduction velocity,SNCV)、腓总神经SNCV、正中神经腓总神经运动神经传导速度(motor nerve conduction velocity,MNCV)、腓总神经MNCV、血清总抗氧化能力(T-AOC)水平均升高,且与B组比较,A组较高(P<0.05)。两组均未发生明显不良反应。结论当归四逆汤治疗DPN可有效改善患者临床症状,减轻机体炎症以及氧化应激反应,稳定患者血糖水平,增强神经传导速度,疗效显著,且安全性较高。

贝前列素钠片治疗周围性面瘫合并糖尿病的疗效研究

目的研究贝前列素钠片治疗周围性面瘫合并糖尿病的临床疗效。方法选取2023年4月—2024年4月福建省泉州市惠安县医院神经内科收治的60例周围性面瘫合并糖尿病患者为研究对象,根据治疗方法的不同分为对照组和观察组,各30例。所有患者均行常规强的松片、抗糖治疗,在此基础上,对照组给予川芎嗪治疗,观察组给予贝前列素钠治疗。治疗8周后,比较两组治疗总有效率、血糖水平、神经传导速度、低血糖与不良反应发生情况。结果治疗后,观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血糖指标(空腹血糖、餐后2 h血糖)、感觉与运动神经传导速度均优于治疗前,且观察组均优于对照组,差异有统计学意义(P均<0.05)。观察组低血糖发生率为6.67%(2/30),低于对照组的26.67%(8/30),差异有统计学意义(χ^(2)=4.320,P=0.038),两组均无大小便失禁、意识丧失等不良反应发生。结论周围性面瘫合并糖尿病患者采用贝前列素钠片治疗,可以显著改善血糖水平、降低不良反应发生率。

加味黄芪桂枝五物汤口服联合当归四逆汤熏洗佐治糖尿病周围神经病变临床评价

目的探讨加味黄芪桂枝五物汤口服联合当归四逆汤熏洗佐治糖尿病周围神经病变(DPN)的临床疗效。方法选取医院2022年7月至2023年11月收诊的DPN患者86例,根据治疗方法的不同分为对照组(41例)和观察组(45例)。两组患者均常规控制血糖、增强免疫及营养神经,观察组患者在此基础上加用加味黄芪桂枝五物汤口服联合当归四逆汤熏洗。两组均以14 d为1疗程,治疗3个疗程。结果观察组总有效率为93.33%,显著高于对照组的78.05%(P<0.05)。治疗后,两组患者的中医证候主症评分、次症评分及总评分均显著降低(P<0.05);多伦多临床评分系统评分均显著降低(P<0.05);腓总神经与正中神经的感觉神经传导速率和运动神经传导速率均显著加快(P<0.05);血清基质金属蛋白酶9、NOD样受体热蛋白结构域3炎性小体水平均显著降低,血清超氧化物歧化酶水平均显著升高(P<0.05);血清丙二醛水平均显著降低(P<0.05);且观察组各指标均显著优于对照组(P<0.05)。两组患者不良反应发生率相当(11.11%比7.32%,P>0.05)。结论加味黄芪桂枝五物汤口服联合当归四逆汤熏洗佐治DPN,可改善患者临床症状,提高神经传导速率,减轻炎性反应与氧化应激反应。

高压氧辅助前列地尔对糖尿病周围神经病变患者腓肠肌神经阈值、运动和感觉神经传导速度的影响

目的探究高压氧辅助前列地尔对糖尿病周围神经病变(DPN)患者腓肠肌神经阈值、运动和感觉神经传导速度的影响。方法选取临沂市中医医院2020年9月—2023年9月收治的82例DPN患者为研究对象,按随机数字表法将其分为对照组与观察组,各41例。对照组采用前列地尔治疗,观察组在对照组基础上联合高压氧治疗,于治疗20 d后评估。比较两组的临床疗效、腓肠肌神经阈值、运动和感觉神经传导速度、不良反应发生率。结果观察组治疗总有效率较对照组高,差异有统计学意义(P<0.05)。治疗前,两组腓肠肌神经阈值、运动和感觉神经传导速度比较,组间差异无统计学意义(P>0.05);治疗后,观察组左侧、右侧腓肠肌神经阈值均较对照组低,运动及感觉神经传导速度均较对照组快,组间差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论高压氧辅助前列地尔治疗DPN患者可有效降低腓肠肌神经阈值,加快神经传导速度,且安全性高。

辛桂凝胶贴膏对糖尿病大鼠周围神经病变的影响

目的观察辛桂凝胶贴膏(肉桂、细辛、吴茱萸、川芎、冰片)对糖尿病大鼠周围神经病变的影响。方法采用单次腹腔注射1%链脲佐菌素(STZ,35 mg·kg^(-1))复制2型糖尿病大鼠模型后,结合长期(连续8周)高脂高糖饮食诱导产生糖尿病周围神经病变(DPN)。将SD大鼠随机分为正常组、模型组、甲钴胺组及辛桂凝胶贴膏组,每组6只。辛桂凝胶贴膏组大鼠穴位贴敷辛桂凝胶贴膏,每天1次,持续给药8周;甲钴胺组大鼠给予甲钴胺溶液灌胃(0.045 mg·kg^(-1)),正常组、模型组大鼠给予生理盐水灌胃。第2、4、6、8周测量大鼠体质量、空腹血糖(FBG);第4、8周检测大鼠热刺激缩足反应潜伏期(TWL);第8周检测大鼠的坐骨神经传导速度,包括运动神经传导速度(MNCV)及感觉神经传导速度(SNCV);采用全自动生化分析仪检测大鼠血清总胆固醇(TC)、甘油三酯(TG)、FBG水平;采用ELISA法检测空腹胰岛素(FINS)水平,计算胰岛素抵抗指数(HOMA-IR);HE染色法观察大鼠坐骨神经组织病理变化。结果与正常组比较,模型组大鼠体质量、FINS水平显著降低(P<0.01),FBG、TC、TG水平及HOMA-IR显著升高(P<0.05,P<0.01);TWL、MNCV及SNCV显著降低(P<0.01),坐骨神经纤维排列紊乱松散,出现脱髓鞘、轴突萎缩和空泡样现象。与模型组比较,辛桂凝胶贴膏组大鼠体质量及FBG、TC、TG水平无明显变化(P>0.05),FINS水平明显升高(P<0.05),HOMA-IR明显降低(P<0.05);甲钴胺组及辛桂凝胶贴膏组大鼠的TWL、MNCV及SNCV显著升高(P<0.05,P<0.01),坐骨神经病变情况得到不同程度改善,神经纤维排列较规则,髓鞘缺失和轴突萎缩明显改善。结论辛桂凝胶贴膏可以一定程度改善DPN大鼠的胰岛素抵抗,缓解热刺激敏感度,提高坐骨神经传导速度,对糖尿病大鼠的周围神经具有保护作用,但降糖、降血脂作用不明显。

己酮可可碱联合依帕司他对糖尿病周围神经病变患者神经传导功能及TSS评分的影响

目的 探讨己酮可可碱联合依帕司他治疗糖尿病周围神经病变(DPN)的效果及对患者神经传导功能、神经病变症状评分的影响。方法 选取中国人民解放军联勤保障部队第988医院2022年2月至2023年8月DPN患者资料进行回顾性研究,根据不同治疗方案将150例患者以配对原则分为两组,各75例。在常规治疗基础上,予以依帕司他治疗者归为对照组,予以依帕司他+己酮可可碱治疗者归为联合组。对比两组疗效、不良反应、神经病变自觉症状问卷(TSS)评分、密歇根神经病变筛选法(MNSI)评分、神经传导功能[正中神经、腓浅神经的运动潜伏期(LAT)、运动传导速度(MNCV)、感觉传导速度(SNCV)]、促神经病变因子[血皮细胞特异性分子-1(ESM-1)、同型半胱氨酸(Hcy)、内皮素-1(ET-1)、特异性烯醇化酶(NSE)]、血液流变学指标[全血高切黏度(BVH)、红细胞比容(Hct)、红细胞聚集指数(AI)]。结果 联合组总有效率(96.00%)高于对照组(85.33%)(P<0.05);治疗后,联合组TSS、MNSI评分低于对照组(P<0.05);治疗后,联合组正中神经、腓浅神经的LAT低于对照组,MNCV、SNCV高于对照组(P<0.05);治疗后,联合组ESM-1、ET-1、Hcy、NSE、AI、Hct、BVH低于对照组(P<0.05);两组不良反应发生率(联合组9.33%与对照组6.67%)相比,差异无统计学意义(P>0.05)。结论 己酮可可碱联合依帕司他治疗DPN安全、有效,可改善血液流变学指标,减轻血管内皮损伤,提高神经传导功能,促进神经病变症状恢复。

胰激肽原酶肠溶片治疗糖尿病周围神经病变患者的效果

目的:观察胰激肽原酶肠溶片治疗糖尿病周围神经病变(DPN)患者的效果。方法:选取2021年1月至2023年1月该院收治的94例DPN患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各47例。对照组采用硫辛酸联合甲钴胺治疗,观察组在对照组基础上给予胰激肽原酶肠溶片治疗,比较两组临床疗效、治疗前后氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)、总抗氧化能力(T-AOC)]水平和周围神经传导速度[运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)]。结果:观察组治疗总有效率为97.87%(46/47),高于对照组的82.98%(39/47),差异有统计学意义(P<0.05);治疗后,观察组MDA水平低于对照组,SOD、T-AOC水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组正中神经、腓总神经的SNCV、MNCV均高于对照组,差异有统计学意义(P<0.05)。结论:在硫辛酸联合甲钴胺治疗基础上采用胰激肽原酶肠溶片治疗DPN患者可提高治疗总有效率和周围神经传导速度,改善氧化应激指标水平,效果优于单纯硫辛酸联合甲钴胺治疗。

木丹颗粒联合α-硫辛酸与甲钴胺治疗糖尿病周围神经病变疗效及对血清同型半胱氨酸、神经传导速度影响研究

目的 探讨对糖尿病周围神经病变(diabetic peripheral neuropathy,DPN)患者采用木丹颗粒联合α-硫辛酸、甲钴胺治疗的临床效果。方法 选取2019年1月—2020年10月在该院治疗的96例DPN患者为研究对象,采用随机数字表法将其分为对照组和研究组,每组48例。两组患者均给予甲钴胺和α-硫辛酸治疗,研究组在此基础上联合木丹颗粒进行治疗,观察并比较两组患者治疗前后左腓神经、左腓总神经、右腓神经和右腓总神经传导速度,多伦多临床评分系统(TCSS)评分,血清同型半胱氨酸(Hcy)和氧化应激指标[超敏C反应蛋白(hs-CRP)、血清超氧化物歧化酶(SOD)]水平,血液流变学指标水平;两组患者治疗后治疗效果及不良反应发生率。结果 (1)治疗前,两组患者神经传导速度比较差异无统计学意义(P>0.05);治疗后,两组患者神经传导速度较本组治疗前均提高(P<0.05),且研究组各项神经传导速度均快于对照组(P<0.05)。(2)治疗前,两组患者神经症状、感觉功能和神经反射三方面TCSS评分比较差异无统计学意义(P>0.05);治疗后两组患者三方面TCSS评分较本组治疗前均降低(P<0.05),且研究组三方面TCSS评分均低于对照组(P<0.05)。(3)治疗后,研究组治疗总有效率(93.75%)高于对照组(77.08%),差异有统计学意义(P<0.05)。(4)治疗前,两组患者血清Hcy、hs-CRP和SOD水平比较差异无统计学意义(P>0.05);治疗后,两组患者Hcy和hs-CRP水平较本组治疗前均降低(P<0.05),SOD水平较本组治疗前均升高(P<0.05),且研究组与对照组比较差异有统计学意义(P<0.05)。(5)治疗前,两组患者血浆黏度、红细胞体积、纤维蛋白原、全血低切黏度和全血高切黏度5项血液流变学指标水平比较差异无统计学意义(P>0.05);治疗后,两组患者5项血液流变学指标水平较本组治疗前均降低(P<0.05),且研究组水平均低于对照组(P<0.05)。(6)研究组不良反应发生率(22.92%)与对照组(18.75%)比较差异无统计学意义(P>0.05)。结论 α-硫辛酸、甲钴胺和木丹颗粒3种药物联合治疗DPN可以有效改善神经感知异常症状,提高神经传导速度,降低Hcy水平,提高临床治疗效果并保障患者治疗的安全性,联合用药临床价值较高。